Search
Search Results
-
Potential value of ctDNA monitoring in metastatic HR + /HER2 − breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial
BackgroundThere is increasing interest in the use of liquid biopsies, but data on longitudinal analyses of circulating tumor DNA (ctDNA) remain...
-
Clinical implications of CSF-ctDNA positivity in newly diagnosed diffuse large B cell lymphoma
The clinical implications of CSF-ctDNA positivity in newly diagnosed diffuse large B cell lymphoma (ND-DLBCL) remains largely unexplored. One...
-
Circulating Tumor DNA (ctDNA) and Its Role in Gynecologic Malignancies
Circulating tumor DNA (ctDNA) refers to small fragments of DNA released into the bloodstream by cancer cells. It is obtained through “liquid biopsy;"...
-
Perspectives for the clinical application of ctDNA analysis to breast cancer drug therapy
Circulating tumor DNA (ctDNA) consists of DNA fragments released from cancer cells into the blood circulation with quick clearance. Analysis of ctDNA...
-
Plasma ctDNA enhances the tissue-based detection of oncodriver mutations in colorectal cancer
PurposeThe advent of circulating tumor DNA (ctDNA) technology has provided a convenient and noninvasive means to continuously monitor cancer genomic...
-
Pre-radiotherapy ctDNA liquid biopsy for risk stratification of oligometastatic non-small cell lung cancer
The optimal treatment paradigm for patients with oligometastatic non-small cell lung cancer (NSCLC) remains unclear. Some patients with...
-
ctDNA to Guide Treatment of Colorectal Cancer: Ready for Standard of Care?
Circulating tumor DNA (ctDNA) has already shown clinically relevant results in early-stage colon cancer patient management. Its prognostic value is...
-
Liquid Biopsy by ctDNA in Liver Transplantation for Colorectal Cancer Liver Metastasis
IntroductionColorectal cancer is a leading cause of cancer-related death worldwide. Metastatic liver disease develops in 50% of cases and drives...
-
Additional considerations before using a ctDNA-guided approach for informing adjuvant chemotherapy in colorectal cancer
BackgroundThe DYNAMIC trial investigated the use of circulating tumor DNA (ctDNA) to guide adjuvant treatment decisions in stage II colon cancer....
-
Assessing circulating tumour DNA (ctDNA) as a prognostic biomarker in locally advanced rectal cancer: a systematic review and meta-analysis
IntroductionCirculating tumour DNA (ctDNA) has emerged as a promising biomarker in various cancer types, including locally advanced rectal cancer...
-
Construction of a risk stratification model integrating ctDNA to predict response and survival in neoadjuvant-treated breast cancer
BackgroundThe pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) of breast cancer is closely related to a better prognosis....
-
Genomic profiling of NGS-based ctDNA from Chinese non-small cell lung cancer patients
PurposeCell-free circulating tumor DNA (ctDNA) in plasma enables rapid and repeat testing of actionable mutations. Next-generation sequencing (NGS)...
-
Use of Circulating Tumor DNA (ctDNA) for Early Molecular Detection of Breast Cancer Relapse in Patients with Triple-Negative Breast Cancer (TNBC)
Purpose of ReviewThe intent of this review is to discuss the clinical utility of circulating tumor DNA (ctDNA) analysis for molecular residual...
-
A generalizable machine learning framework for classifying DNA repair defects using ctDNA exomes
Specific classes of DNA damage repair (DDR) defect can drive sensitivity to emerging therapies for metastatic prostate cancer. However, biomarker...
-
-
ctDNA for Risk of Recurrence Assessment in Patients Treated with Neoadjuvant Treatment: A Systematic Review and Meta-analysis
BackgroundWe wanted to investigate the association between circulating tumor DNA (ctDNA) detection at baseline, during and after neoadjuvant...
-
ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors
BackgroundIn non-small cell lung cancer (NSCLC) patients receiving immune checkpoint inhibitors (ICIs), higher blood tumor mutational burden (bTMB)...
-
Preoperative serum ctDNA predicts early hepatocellular carcinoma recurrence and response to systemic therapies
BackgroundCirculating tumor DNA (ctDNA) can be useful in tumor diagnosis and surveillance. However, its value in hepatocellular carcinoma (HCC)...
-
Early detection and stratification of lung cancer aided by a cost-effective assay targeting circulating tumor DNA (ctDNA) methylation
BackgroundDetection of lung cancer at earlier stage can greatly improve patient survival. We aim to develop, validate, and implement a cost-effective...
-
Searching for the “Holy Grail” of breast cancer recurrence risk: a narrative review of the hunt for a better biomarker and the promise of circulating tumor DNA (ctDNA)
BackgroundThis paper is a narrative review of a major clinical challenge at the heart of breast cancer care: determining which patients are at risk...
